Drugs / 1650-G
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01829373 | Oct 2011 → Jun 2012 | lung cancer | Edward Hirschowitz | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00654030 | Oct 2006 → Nov 2009 | non-small cell lung carcinoma | Edward Hirschowitz | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1650-G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00654030 ↗ |
| Modality | Vaccine | “This report describes early clinical experience with vaccine 1650-G, an allogeneic cellular vaccine” PMID 21150468 ↗ Jan 2011 |